Posters

June 15, 2022

The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models

Research and Publications

Publications and Presentations

March 7, 2013

The Hippo Pathway and Human Cancer

Publications and Presentations

November 5, 2015

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

News

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics